Aquestive Therapeutics Files 8-K
Ticker: AQST · Form: 8-K · Filed: Apr 29, 2024 · CIK: 1398733
| Field | Detail |
|---|---|
| Company | Aquestive Therapeutics, Inc. (AQST) |
| Form Type | 8-K |
| Filed Date | Apr 29, 2024 |
| Risk Level | low |
| Pages | 4 |
| Reading Time | 5 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, sec-filing
Related Tickers: AQST
TL;DR
AQST filed an 8-K for financial updates, nothing major yet.
AI Summary
Aquestive Therapeutics, Inc. filed an 8-K on April 29, 2024, reporting on events that occurred on April 26, 2024. The filing primarily concerns financial statements and exhibits, indicating a routine update or disclosure related to the company's financial status and operations. No specific material events like acquisitions or major executive changes were detailed in the provided excerpt.
Why It Matters
This 8-K filing provides an update on Aquestive Therapeutics' financial statements and exhibits, which is important for investors to monitor the company's financial health and operational disclosures.
Risk Assessment
Risk Level: low — The filing appears to be a routine disclosure of financial statements and exhibits, without immediate news of significant events that would typically increase risk.
Key Players & Entities
- Aquestive Therapeutics, Inc. (company) — Registrant
- 0001628280-24-018802 (filing_id) — Accession Number
- 20240426 (date) — Date of earliest event reported
- 20240429 (date) — Date of Report
- 30 Technology Drive Warren, NJ 07059 (address) — Principal Executive Offices
FAQ
What is the primary purpose of this 8-K filing by Aquestive Therapeutics, Inc.?
The primary purpose of this 8-K filing is to report on 'Other Events' and 'Financial Statements and Exhibits' as of April 26, 2024.
When was this 8-K report filed with the SEC?
This 8-K report was filed with the SEC on April 29, 2024.
What is the company's principal executive office address?
The company's principal executive office is located at 30 Technology Drive, Warren, NJ 07059.
What is the Commission File Number for Aquestive Therapeutics, Inc.?
The Commission File Number for Aquestive Therapeutics, Inc. is 001-38599.
Does the filing indicate any significant new developments or material changes?
Based on the provided excerpt, the filing indicates a report on financial statements and exhibits, but does not detail any specific new material events or significant developments.
Filing Stats: 1,263 words · 5 min read · ~4 pages · Grade level 16.8 · Accepted 2024-04-29 09:30:01
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share AQST Nasdaq Global Market I
Filing Documents
- aqst-20240426.htm (8-K) — 34KB
- libervantfdaapprovalprwi.htm (EX-99.1) — 20KB
- libervantfdaapprovalprwi001.jpg (GRAPHIC) — 268KB
- libervantfdaapprovalprwi002.jpg (GRAPHIC) — 252KB
- libervantfdaapprovalprwi003.jpg (GRAPHIC) — 235KB
- libervantfdaapprovalprwi004.jpg (GRAPHIC) — 298KB
- libervantfdaapprovalprwi005.jpg (GRAPHIC) — 206KB
- 0001628280-24-018802.txt ( ) — 1920KB
- aqst-20240426.xsd (EX-101.SCH) — 2KB
- aqst-20240426_lab.xml (EX-101.LAB) — 21KB
- aqst-20240426_pre.xml (EX-101.PRE) — 12KB
- aqst-20240426_htm.xml (XML) — 3KB
01
Item 8.01 Other Events. On April 29, 2024, Aquestive Therapeutics, Inc. ("Aquestive" or the "Company") issued a press release announcing that the U.S. Food and Drug Administration (FDA) approved the Company's drug candidate Libervant (diazepam) Buccal Film for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity ( i.e. , seizure clusters, acute repetitive seizures) that are distinct from a patient's usual seizure pattern in patients with epilepsy between 2 to 5 years of age. The Company also announced in the same press release that the Company's Anaphylm (epinephrine) Sublingual Film clinical development program remains on track to complete the remaining clinical studies required for the submission of the New Drug Application (NDA) for Anaphylm, which submission is planned for the end of 2024. A copy of the Company's press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated into this Item 8.01 by reference. Cautionary Note Regarding Forward-Looking Statements Certain statements in this Current Report on Form 8-K include "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "believe," "anticipate," "plan," "expect," "estimate," intend," "may," "will," or the negative of those terms, and similar expressions, are intended to identify forward-looking statements. These forward-looking statements include, but are not limited to, statements regarding the Company's ability to expand its distribution capabilities and related timing of any distribution expansion and access to patients for Libervant (diazepam) Buccal Film, regarding the advancement and related timing of our product candidate Anaphylm (epinephrine) Sublingual Film through clinical development and approval by the FDA, including expected clinical studies and clinical study dates, the timing of the pre-NDA meeting and Aquestive's goal of filing an NDA for Anaphylm before t
Financial Statements and Exhibits
Financial Statements and Exhibits (d)Exhibits. Exhibit Number Description 99.1 Press Release of the Company issued on April 29, 2024 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: April 29, 2024 Aquestive Therapeutics, Inc. By: /s/ A. Ernest Toth, Jr Name: A. Ernest Toth, Jr. Title: Chief Financial Officer